ADCT-301 is being developed for the treatment of CD25-expressing lymphoma and leukemias.

In lymphoma, a Phase I clinical trial with ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (Study NCT02432235) is open for enrolment and ongoing. To read more about HL and NHL, click here and here, respectively.

In leukemia, a Phase I clinical trial with ADCT-301 in patients with relapsed/refractory CD25-positive acute myelogenous leukemia (AML) and CD25-positive acute lymphoblastic leukemia (ALL) (Study NCT02588092) is open for enrolment and ongoing. To read more about AML and ALL, click here and here, respectively.

To read more about our clinical trials with ADCT-301, click here.